In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

The latest job cuts at Illumina’s California headquarters are not part of a broad-based reduction, a company spokesperson ...

Update 9.22 AM EST: Adds comments from Illumina The EU regulators on Friday approved plans by U.S. genomics company Illumina (NASDAQ:ILMN) to divest Grail, the cancer test developer it acquired in ...

Thaysen has had to deal with orchestrating Illumina’s comeback strategy and the loose ends related to unwinding the company’s ...

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition and innovation in the US.

Illumina's financial flexibility declined a bit to purchase Grail, but given the use of equity and limited debt, Illumina's balance sheet remains lightly leveraged. As of December 2023 ...